Objectives: We investigated the epidemiological, clinical, microbiological and genetic characteristics of linezolidresistant (LZR) Staphylococcus capitis isolates from French ICUs, and compared them with LZR S. capitis isolates from other European countries.
Introduction
Because of the worldwide emergence of multiresistant pathogens, linezolid has been used increasingly since 2000. Not surprisingly, linezolid-resistant (LZR) isolates have subsequently been reported. 1, 2 The LZR phenotype is related to mutations in domain V of the 23S rRNA sequence or in 50S rRNA, or to the acquisition of the cfrA, cfrB and optrA genes. 3, 4 Nowadays, 1%-2% of CoNS harbour resistance to linezolid. 5 Staphylococcus capitis, a usually multi-susceptible and lowvirulence commensal species, has been reported in neonates with sepsis as well as in adult patients suffering endocarditis or bone infections. [6] [7] [8] [9] Among these S. capitis infections, some isolates were multiply resistant, including resistance to methicillin and decreased susceptibility to glycopeptides, for which linezolid has been proposed as a useful alternative drug. 6, 7, 9 Further, it is noteworthy that LZR S. capitis isolates have been reported not only in sporadic cases, but also as a cause of local outbreaks. [10] [11] [12] In this study, we aimed to (i) investigate clinical and molecular characteristics of LZR S. capitis strains isolated in French hospitals, (ii) compare these strains with LZR isolates from other European countries and (iii) determine the distribution and epidemiology of LZR S. capitis strains in France.
Methods

French bacterial isolates and patients
All the LZR S. capitis isolates available in the collection of the French National Reference Center for Staphylococci (NRCS, Hospices Civils de Lyon) were included in the study. Species identification was performed by MALDI-TOF MS (bioMérieux, Marcy-l' Etoile, France). For each isolate, clinical data, including age, sex, comorbidities, previous exposure to linezolid and clinical outcome of the patient, were collected retrospectively and the data were anonymized.
Antimicrobial susceptibility testing (AST)
The AST profiles of the isolates were determined using the standard agar diffusion technique as recommended by the French Society for Microbiology (http://www.sfm-microbiologie.org/UserFiles/files/casfm/ CASFM_EUCAST_V1_2015.pdf). The following antibiotics were tested: penicillin, oxacillin, gentamicin, tobramycin, erythromycin, tetracycline, ofloxacin, trimethoprim/sulfamethoxazole, fusidic acid, rifampicin, vancomycin, teicoplanin, daptomycin and linezolid. MICs of vancomycin, teicoplanin, linezolid and daptomycin were determined using Etest V R in accordance with the manufacturer's instructions. MICs were interpreted according to EUCAST guidelines (http://www.eucast.org/fileadmin/src/media/PDFs/ EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table_non-protected_ preliminary_151207.xls).
Genetic determinants of linezolid resistance
The cfr gene was sought by a specific PCR. 13 Domain V of the 23S rRNA of each isolate was also amplified by PCR as described previously; 14 the PCR products were sequenced on both strands, then aligned with the corresponding sequence of the linezolid-susceptible strain S. capitis CR01 (ENA accession number LN866849) to detect mutations. Subsequently, the allele quantification pyrosequencing method was used to assess the number of 23S rRNA copies harbouring mutations, as previously described. 15 For analysis of ribosomal proteins (L3, L4 and L22, encoded by rplC, rplD and rplV genes, respectively), we used WGS-derived data to compare the gene sequences with those of the publicly available linezolid-susceptible S. capitis genome CR01.
PFGE
To investigate the genetic relatedness of the isolates, PFGE was performed using the SmaI restriction enzyme, 6 with S. capitis CR01 as comparator. 16 Cluster analysis was performed using BioNumerics software 7.1 (Applied Maths NV, Sint-Martens-Latem, Belgium) and pattern similarities >80% (UPGMA, Dice coefficient) were used to define a pulsotype.
17
WGS
To assess the phylogenetic relationships among S. capitis strains, WGS was performed using Illumina technology (HiSeq). The sequences were then compared with the seven publicly available S. capitis genomes: CR01 (ENA accession number LN866849), SK14 (GenBank reference sequence ACFR00000000.1), VCU116 (GenBank reference sequence AFTX00000000.1), QN1 (GenBank reference sequence AJTH00000000.1), LNZR-1 (GenBank reference sequence JGYJ00000000.1), C87 (GenBank reference sequence ACRH00000000.1) and AYP1020 (ENA accession number CP007601). To infer phylogenetic trees from whole-genome sequence data, the REALPHY 1.10 online pipeline 18 with default parameters was used. The closed genome of S. capitis CR01 was used as reference.
Comparison with non-French isolates
The Staphylococcal Research Laboratories (SRLs) of all European countries were invited to send LZR S. capitis isolates from their collection to the French NRCS. Isolates were then characterized by AST, 23S rRNA and ribosomal protein mutation screening, cfr and optrA detection and PFGE. One representative isolate per country was also subjected to WGS. The overall data were compared with those obtained for the French isolates.
Epidemiological study
Retrospective epidemiological data concerning S. capitis recovered from adult patients during 2014 (number, site of isolation, AST profiles) were collected from bacteriological laboratories of 47 French university hospitals, using a standardized questionnaire. To avoid duplicates, only the first S. capitis isolate per patient was included in this study.
Results
French strains and patients
A total of nine isolates were included from the adult ICUs of three geographically distant French hospitals (Bayonne n ¼ 5, Lille n ¼ 2, Strasbourg n ¼ 2). The clinical characteristics of the nine patients are presented in Table 1 . Only five patients had previously received linezolid therapy, on average 27 days prior to isolation of the LZR S. capitis.
The AST profiles of the nine isolates are presented in Table 2 . All isolates were resistant to linezolid (MIC >4 mg/L), penicillin, methicillin and aminoglycosides. Additional resistance to teicoplanin and daptomycin was variable.
Analysis of the 23S rRNA sequences identified the same mutation (G2576T) in all the isolates, with three to five mutated copies over a total of six copies of 23S rRNA. The cfrA, cfrB and optrA genes were absent and no mutation was detected in the ribosomal proteins L3, L4 and L22.
Comparison with other European isolates and genetic relationship of the strains
Twenty-one SRLs were asked to send LZR S. capitis isolates from their collection: 5 SRLs out of 21 indicated that there were no LZR S. capitis isolates in their collection and 14 SRLs did not answer our request. We collected LZR S. capitis from two SRLs: Greece (n ¼ 11; recovered between 2011 and 2015) and Finland (n ¼ 1; isolated in 2015). These 12 isolates shared the same AST profile with the French ones, associated with variable resistance to daptomycin for 8 isolates and harboured the same genetic determinant of linezolid resistance (G2576T mutation of the 23S rRNA, no cfr gene, no optrA gene and no ribosomal protein mutation) ( Table 2 ). Of note, pyrosequencing was not performed on these isolates because the results obtained for the French isolates did not show any correlation between linezolid MICs and the number of 23S rRNA mutated copies.
European linezolid-resistant S. capitis clone JAC PFGE analysis showed that the 9 French and 12 European isolates shared >80% similarity in their SmaI macrorestriction pulsotype, and so could be considered as belonging to the same clone ( Figure 1) .
Analysis of the WGS of 11 LZR S. capitis isolates (9 from France, 1 from Greece and 1 from Finland) and the seven publicly available S. capitis genomes showed the genomes shared a total of 1 484 569 homologous sites, constituting the core genome used for the phylogenetic reconstruction ( Figure 2 ). All 11 LZR S. capitis strains clustered in a single independent clade, confirming they belong to a clonal population. Of note, the linezolid-susceptible AYP1020 strain was phylogenetically close to this clone. We observed a maximum of 212 SNPs between all the LZR S. capitis genomes, whereas comparison with the other S. capitis genomes All the isolates harboured the same G2576T mutation in the 23S rRNA. The cfr and optrA genes were absent from all isolates. No mutation was detected in the ribosomal proteins L3, L4 and L22 for all isolates. All the isolates were resistant to penicillin, oxacillin, gentamicin and tobramycin. Butin et al.
showed 373 SNPs versus the AYP1020 genome, and 10 767-47 863 SNPs when compared with the other publicly available S. capitis genomes.
French epidemiological study
Based on a retrospective study of AST data generated routinely in 47 French hospitals in 2014, a total of 35 S. capitis strains harboured the same AST profile as the clone reported here (resistance to methicillin, aminoglycosides and linezolid). The isolates were recovered from adult patients in 7 of the 47 French hospital centres participating in this study. This represents 1% of all S. capitis strains (n ¼ 2821) isolated during this period in the 47 hospitals, but 12%, 4% and 10% from Bayonne, Lille and Strasbourg, respectively (the three hospitals from which the nine French strains included in this study had been collected). The remaining 26 clinical isolates were not sent to the French NRCS and not stored and so were unavailable for further analysis.
Discussion
The collective data indicate an LZR S. capitis clone, present in at least three European countries, harbouring the common multiple resistance profile and G2576T mutation. The clonality of these S. capitis isolates has been established by both PFGE and WGS analyses. Further, epidemiological data from French hospitals suggest that, when present, this clone may represent up to 12% of all S. capitis strains. The 21 isolates characterized in our study were all resistant to methicillin, aminoglycosides and linezolid. This multiply resistant profile is unusual because S. capitis is classically reported as a broadly antibiotic-susceptible CoNS species. 19 Some isolates were also resistant to glycopeptides and/or daptomycin, consequently reducing therapeutic options, which is worrisome.
One limitation of our study concerns possible ascertainment bias. LZR isolates are not systematically stored and not routinely referred by hospitals to the French NRCS so the data herein likely reflect an underestimate of the scale of diffusion of this clone in France. Interestingly, because the AST profile of this clone is very unusual within the S. capitis species, it is likely that all the S. capitis isolates harbouring this specific profile belong to this clone. On the basis of the epidemiological nationwide study reported herein, the clone has been detected in at least seven hospitals in France. Similarly, at the European scale, the clone has been identified sporadically in Greece and Finland, but data are lacking from 14 out of 21 SRLs, suggesting it may be present on a wider scale in Europe. It would be interesting to initiate a prospective study to collect LZR S. capitis isolates from other hospitals/countries throughout Europe to better monitor the geographical distribution, diffusion and evolution of this clone. Figure 1 . Dendrogram of 21 clinical LZR S. capitis strains isolated from France, Greece and Finland. The PFGE dendrogram was generated from SmaI PFGE patterns using BioNumerics software 7.1, as previously described. S. capitis CR01 was included as comparator. The vertical dotted line represents the 80% limit of similarity.
European linezolid-resistant S. capitis clone JAC LZR S. capitis isolates have been reported sporadically in the literature. [10] [11] [12] However, our results constitute the first report of a widespread diffusion of a single LZR CoNS clone in several countries. It raises important questions regarding the origin and dissemination of this clone. The clonality of the present S. capitis isolates is remarkable because pulsotypes of S. capitis isolates from adult patients show a high diversity. 6 This unexpected genetic relationship contrasts with the distant geographical origins of the cases and could be related to a wide inter-hospital dissemination of the clone as reported for Staphylococcus aureus. 20 Another hypothesis, which cannot be excluded, although it is unlikely, is an intrinsic ability of the clone to acquire (following dissemination) resistance to linezolid due to hypermutator features. Similarly, in a recent study, Karavasilis et al. 21 reported the multicentre distribution of an LZR ST22 Staphylococcus epidermidis clone in six different hospitals in Greece. The authors found that the linezolid dependence of this clone constitutes a selective advantage when exposed to linezolid and enabled its wide dissemination. No data support this phenomenon in the present S. capitis clone. However, given that it is well documented that emergence of LZR isolates is favoured by the widespread use of linezolid within a setting, 22 appropriate antimicrobial stewardship initiatives are urgently required to preserve the therapeutic effectiveness of linezolid and to preserve the hospital bacterial ecology. This is made more imperative in view of the marketing of generic medicinal products for linezolid, thereby reducing the cost and increasing prescribing.
G2576T is the most frequent mutation described in LZR CoNS Interestingly, although all the isolates explored in the present study harbour the same mutation in the 23S rRNA and no mutation in the ribosomal proteins, they show different linezolid MICs.
In particular, we observed that linezolid MICs of the five successively isolated strains in Bayonne hospital increased over time (12, 64 then >256 mg/L), suggesting a time-dependent adaptation of a single resistant strain under linezolid selective pressure in the same environment. No correlation between the number of mutant 23S rRNA copies and linezolid MIC levels was apparent. This lack of correlation had already been observed for LZR S. capitis isolates by Takaya et al.; 12 the authors suggested that it may reflect other mutations, drug efflux or other unidentified associated mechanisms.
Another important observation is the local outbreak potential or persistence of this clone, as evidenced by the high proportion of strains harbouring the specific AST profile of the clone among all S. capitis isolates identified in two hospitals (10% in Strasbourg and 12% in Bayonne in 2014). Second, we observed that in Bayonne hospital five strains belonging to the clone had been isolated from five different patients over a 20 month period. The only relationship Figure 2 . SNP-based maximum likelihood tree of WGS of 11 LZR S. capitis isolates and publicly available S. capitis genomes. A total of 1 484 569 homologous sites from all 18 genomes (polymorphic and non-polymorphic sites) were obtained using the REALPHY 1.10 online pipeline. The closed chromosome of S. capitis CR01 (ENA accession number LN866849) was used as reference. A maximum likelihood tree was built using PhyML with default parameters as implemented in REALPHY 1.10. between the five patients was their hospitalization in the same ICU. Of note, there was a 6 month period between the discharge of the second patient and the admission of the third patient (data not shown). This could suggest a latent persistence of the clone in the ICU, either in the hospital environment, as described previously for LZR E. faecium strains, 24 or in asymptomatic carriers (inpatients and/or healthcare workers). Furthermore, in Bayonne, three of the five patients had not received linezolid therapy before recovery of the LZR strain, which implies inter-patient transmission of an LZR strain within the ICU without a direct selective pressure of linezolid. Therefore, a reinforcement of strict hygiene measures would be prudent to limit the intra-ICU diffusion of this multiply resistant clone, especially in critically ill patients.
Finally, the close genetic relatedness of our clone with the AYP1020 genome is surprising, since the latter is a fully susceptible isolate. 25 A detailed analysis of this genome showed high similarity of its core genome with the core genomes of the LZR strains of this study (data not shown). To date, no explanation can be proposed for this unexpected clustering. AYP1020 could be a representative of the precursor lineage from which the LZR clone emerged, but no epidemiological data are currently available to confirm this hypothesis.
Conclusions
Emergence and wide inter-hospital diffusion of the LZR CoNS clone in several European countries is worrisome and unexpected because S. capitis is usually a multi-susceptible, low-virulence species. The possible hitherto unrecognized wider distribution of this clone, its association with disease, its propensity for acquiring resistance, the mechanisms involved and its evolution require further studies.
